Prophylaxis for travel‐related thrombosis? No
A. Lubetsky
DOI: https://doi.org/10.1111/j.1538-7836.2004.01020.x
2004-12-01
Journal of Thrombosis and Haemostasis
Abstract:In 1954, Homans reported on the association between travel and venous thromboembolism (VTE). Fifty years later, we have learned a great deal more about this association, and today, in 2004, we are able to state that: Travel and thrombosis are associated. Four case–control studies [1–4] and five cohort and randomized controlled studies [5–9] have clearly established that thrombosis is associated with travel. In the four case–control studies about 13%of patients with venous thromboembolism had a history of recent travel, by air or other means of transportation, compared with 7% of controls. Although two studies [3,10] failed to detect a direct association between travel and thrombosis, all other case–control studies [1,2,4], cohort studies [7,8,11] and randomized trials [9] showed positive associations. In the cohort studies (and in the control arms of randomized studies) figures were somewhat lower—about 3% of patients suffered a thrombotic event following air travel. Two of these studies [7,8] recruited patients who responded to media ads looking for volunteers (and therefore represented a selected group of patients); however, both studies have shown that the risk for thrombosis (1.0–2.8%) was clearly associated with air travel. The predisposition to VTE is patientand travel-related. It is evident from most of the studies published to date that most VTE episodes occur in patients with baseline risks for thrombosis. Patient-related risk factors include a previous deep vein thrombosis (DVT) episode, severe obesity or limitation of mobility, neoplastic disease in last 2 years or large varicose veins [5,6], whereas in other studies surgery, pregnancy, hormone use, and a family history of thrombosis were also considered risk factors. In the absence of these risk factors the rate of DVT was 0% (among 355 such low-risk patients), whereas the rate was 2.7% in high-risk patients [5]. A documented thrombophilic disorder was also recognized to be a significant risk factor in recent studies and to increase the risk as high as 17-fold in air travelers in one such study [4]. Prolonged sitting in cramped quarters is a significant travel-related risk factor. Both stasis of blood in leg veins and possible effect of pressure exerted by the seat edge on calf muscles promote clot formation. This was already suggested by Homans in 1954 and is further stressed by the fact that many patients suffering a VTE episode never leave their seats during flight (95% of patients with major pulmonary embolism in the report by Lapostolle et al. [11]) or occupy a window or middle seat (76% of patients in the LONFLIT studies [6]). Unique to the situation of air travel are cabinrelated risk factors. Hypoxemia, low cabin humidity, and dehydration leading to changes in plasma viscosity, reduced fibrinolytic activity and to activation of coagulation have all been proposed as underlying mechanisms [12], but their contribution to the thrombotic risk beyond the abovementioned risk factors is uncertain. To summarize: identification of the various risk factors in each traveler will potentially enable physicians to classify patients according to their personal risk profile and identify patients as belonging to low, intermediate or high-risk groups for thrombosis. Prophylactic means are available and are effective. Recent studies suggest that VTE secondary to prolonged air travel is preventable. In two randomized, controlled studies [5,9] patients allocated to wear elastic compression stockings (ECS) during air travel had a significantly reduced risk of thrombosis (0–0.24% compared with 4.5–10.0% in controls). In another study [6] administration of a single dose of low-molecular-weight heparin (LMWH) prevented occurrence of VTE completely, whereas administration of aspirin failed to do so. Taking into consideration the above-mentioned points, one could easily be tempted to use VTE prophylaxis for all travelers. However, routine prophylaxis for all travelers is not necessary, and occasionally may be harmful. Although many patients suffering a new travel-related VTE episode will eventually be identified as having at least one comorbid condition, using female hormones or carrying some form of thrombophilia [11], this is not true for all travelers. From the prospective studies it is evident that around 6–10% of patients carry some form of thrombophilia, up to 30% use female hormones and around 40% have some comorbid condition [8], Correspondence: A. Lubetsky, National Hemophilia Center and Institute of Thrombosis and Hemostasis, Sheba Medical Center, TelHashomer, Israel 52621. Tel.: +972 3 53